Table 2.

Vaccine efficacy of recombinant COVID-19 vaccine (Ad5-nCoV-IH) in preventing virologically confirmed COVID-19 cases at 14 days after vaccination

Median follow-up days	Ad5-nCoV-IH n/N (%)	BNT-IM n/N (%)	VE (95% CI)	aVE (95% CI)
60 days	22/270 (8.1%)	26/269 (9.7%)	0.17(-0.46-0.53)	0.19(-0.43-0.55)
90 days	26/270 (9.6%)	31/269 (11.5%)	0.18(-0.38-0.51)	0.2(-0.35-0.53)
120 days	27/270 (10.0%)	33/269 (12.3%)	0.2(-0.32-0.52)	0.22(-0.3-0.53)
169 days (full time)	34/270 (13.7%)	35/269 (13.0%)	0.06(-0.51-0.41)	0.07(-0.49-0.42)

N number of participants in each data set, n actual number of COVID-19 cases, Ad5-nCoV-IH Recombinant Covid-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation, BNT-IM intramuscular tozinameran vaccine, VE vaccine efficacy, aVE adjusted vaccine efficacy.